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nificant periprocedural complications associated with the laser
technique (including pericardial tamponade or effusions in 7.0% of
patients, and ventricular arrhythmias necessitating cardioversion in
5.6%), without enduring improvement in symptoms or exercise
tolerance (2). Perin and Colleagues bemoan the lack of 12-month
follow-up in our study. Unfortunately, such data was requested and
not supplied by the sponsor. Moreover, the weak trend in our study
toward less angina in PMR-treated patients at 3 months was
diminishing at 6 months, making it doubtful that 12-month
follow-up would have revealed significant symptomatic improve-
ment. Their second comment reiterates our acknowledged limita-
tion that the rate of paired exercise testing was lower than
anticipated. However, as statistically discussed in the report (2),
given the observed mean difference in exercise tolerance of only
17 s between groups, it is highly unlikely that a greater number of
patients would have altered our conclusions.
Third, Perin et al. question the fact that our study was
adequately blinded, which may have contributed to the negative
findings. This is counterintuitive; lack of blinding would have
favored the active treatment group, making the trial more positive.
Moreover, it is unclear how blinded the BELIEF study was; the
laser in the sham group was connected to a “lead box,” which likely
precluded the characteristic visual and acoustic signals when the
laser was fired. This small (only 82 randomized patients) though
well-designed study also showed no difference in exercise tolerance
between PMR and placebo groups, and incremental improvement
in angina by 1 class at 12 months in only 24% of treated patients
(n  10), which may have been due to chance given the small
sample size (3). We therefore cannot agree with their statement
that BELIEF has “effectively addressed” the placebo question,
given the results of the much larger, blinded DIRECT trial (4).
Finally, although we agree with Perin and Co-workers that the
three holmium yttrium-aluminium-garnet (YAG) laser systems
subjected to clinical trials are different, and stated so in the last
paragraph of our report (2), we strongly disagree with their
statement that “Based on the negative outcome for the DIRECT
trial utilizing the DMR system, it is clear that fiberoptic penetra-
tion into the myocardium and significant channel formation, as
with PMR, are essential to achieving clinical benefit.” Evaluating
whether the different modes of energy delivery or myocardial
penetration has anything to do with clinical efficacy would require
a comparative study between the two systems, or absent this, at
least a positive adequately sized multicenter blinded study of PMR
using the CardioGenesis system.
We suggest that rather than arguing the merits of the currently
completed trials, all of which are flawed to some degree, Perin et
al. focus on lobbying for an adequately powered, appropriately
blinded clinical trial to once and for all either prove the safety and
efficacy of PMR, or, alternatively, demonstrate its futility. Other-
wise, it is doubtful that this once promising approach will ever
become widely accepted by the clinical community.
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Stented Angioplasty or Coronary Artery
Bypass Graft Surgery for Multivessel Disease?
The recent report from the ARTS trial focuses on the effect of
completeness of revascularization on the outcome within each
cohort (1). In the previous report from the trial, on the basis of a
small difference in the cost of treatment during the first year in
favor of stented angioplasty, but in the absence of difference in the
rate of major complications and with a repeat revascularization rate
more than five times greater among the stented patients, the
investigators concluded that there is no advantage to surgery over
angioplasty in patients with multivessel disease (2). Now we learn
that when the interventional cardiologists estimated that, using
stented angioplasty, they could achieve a degree of revasculariza-
tion equal to surgical revascularization, they were, in fact, able to
provide this degree of completeness to a substantially lower
number of patients (70.5% vs. 84.1%). The significantly better
revascularization in the surgical group was accomplished without
increased incidence of stroke, myocardial infarction, or death.
Patients in this trial, who were randomized to stented angioplasty
and received incomplete revascularization (30%), could have much
better freedom from death and other major complications, reduc-
ing the need for subsequent bypass surgery from 10% to only 0.2%
to 1.1%, with only minimal effect of completeness of revascular-
ization. However, the investigators elected to emphasize the effect
of complete revascularization; the fact that even with complete
revascularization, the stented patients had a one-year event-free
survival much inferior to their surgical counterparts does not
appear, as it should, in the conclusions of their report.
Another unanswered question is what happened to the left
ventricle (LV) using an approach that resulted in the need for
repeat revascularization in every fifth patient. Were all the ischemic
episodes indicating the need for further revascularization proce-
dures free of irreversible myocardial damage? And was the subse-
quent procedure, carrying a 5% to 6% infarction rate in the index
procedure, free of damage the second time? Has LV function
remained unchanged in both groups?
The researchers conclude that the effectiveness and cost-
effectiveness of angioplasty can be further enhanced by careful
selection of patients. The cohort assigned to this study consisted of
lesser proportion of patients with totally obstructed vessels, small
or multilesion vessels, and at least two lesions in arteries 2.75
mm, leading to two different territories. Such patients are almost
ideal candidates for angioplasty. Careful selection of candidates
from among these patients will further limit the application of the
study results to the entire population of patients with multivessel
disease.
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As surgical collaborators in this study, we think that it shows
that the most appropriate approach to patients with multivessel
disease is apparent from this and the previous report from the
ARTS trial. This could not have been expressed better than in the
last sentence in the Results section, which should have been moved
to the Conclusions section of the report.
Amir Elami, MD
The Department of Cardiothoracic Surgery
Hadassah University Hospital
Jerusalem 91120, Israel
E-mail: eamir@md.huji.ac.il
Gideon Merin, MD
PII S0735-1097(02)02573-1
REFERENCES
1. van den Brand MJBM, Rensing BJWM, Morel MM, et al. The effect
of completeness of revascularization on event-free survival at one year in
the ARTS trial. J Am Coll Cardiol 2002;39:559–64.
2. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary artery
bypass surgery and stenting for the treatment of multivessel disease.
N Engl J Med 2001;344:117–24.
REPLY
We have read with interest the comments of Doctors Elami and
Merin relating to our study “The Effect of Completeness of
Revascularization on Event-free Survival” (1). It is remarkable that
the title of their communication is “Stented Angioplasty or
Coronary artery Bypass Graft Surgery for Multivessel Disease?”
Indeed, most of their comments apply to the general results of the
ARTS trial as published by Serruys et al. (2). The reasoning
behind our study was threefold. First, both angioplasty and surgery
have a substantial number of patients left with anatomical incom-
plete revascularization. This means that interventional cardiolo-
gists should seek optimal patient selection to achieve complete
revascularization, as this leads to a 7% higher event-free survival at
one year. Surgeons also could do better, as they achieve complete
revascularization in only five out of six patients, albeit without a
significant difference in outcome between both groups at one year.
Second, even with incomplete percutaneous revascularization,
the number of irreversible events was not higher than for the other
three subgroups, as can be learned from Table 3 of our report.
Thus, the higher number of revascularizations in the (PCI)
patients did not lead to a higher number of infarctions, although
left ventricular function has not routinely been measured at
follow-up. This means that within the selection criteria of the
ARTS trial, the patient and the doctor could opt for intentionally
incomplete percutaneous revascularization without endangering
the patient’s life expectancy and without infarcts and cerebrovas-
cular accidents. This still appeals to numerous patients as an
agreeable alternative to surgery, notwithstanding the advances that
have been made in surgical techniques. At one year, 98% of PCI
patients with complete revascularization were free from coronary
artery bypass graft surgery (CABG) compared to only 90% of the
incompletely percutaneously revascularized patients.
Third, in European countries the portion of PCI in the total
number of coronary revascularizations is between 40% and 70% (3).
Nevertheless, the vast majority ot these percutaneous revascu-
larizations are still performed in patients with single-vessel disease
(e.g., 86% in The Netherlands; database BHN, first quarter 2002).
The ARTS trial was developed to explore the outcome of
multivessel-stented PCI. In retrospect, we tried to investigate
whether incomplete and complete revascularization had the same
effect on percutaneously and surgically treated patients. We found
that patients incompletely revascularized with PCI needed more
reinterventions. To enhance the outcome of multivessel PCI, we
concluded that complete revascularization is a good guarantee for
survival without CABG, with a 13% re-PCI rate. If the promises
of rapamycin-coated stents are confirmed (4), and restenoses are
prevented, complete PCI revascularization can compete with
surgery, not only in preventing surgery, but also making it a
one-time procedure like surgery. But even without restenosis,
careful selection of patients to achieve complete revascularization is
a prerequisite for event-free survival after PCI.
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